Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study

Diabetes Res Clin Pract. 2013 May;100(2):e55-8. doi: 10.1016/j.diabres.2013.01.020. Epub 2013 Mar 13.

Abstract

Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.

Trial registration: ClinicalTrials.gov NCT01235819.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Exenatide
  • Female
  • Humans
  • Insulin / therapeutic use*
  • Male
  • Peptides / therapeutic use*
  • Pyrazines / therapeutic use*
  • Sitagliptin Phosphate
  • Treatment Outcome
  • Triazoles / therapeutic use*
  • Venoms / therapeutic use*
  • Young Adult

Substances

  • Insulin
  • Peptides
  • Pyrazines
  • Triazoles
  • Venoms
  • Exenatide
  • Sitagliptin Phosphate

Associated data

  • ClinicalTrials.gov/NCT01235819